Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05474417 · ClinicalTrials.gov registry record
The Effects of the CF Carrier State on the Kidneys and Pancreas
A clinical trial of Kidney Diseases and Pancreatic Disease, sponsored by Philip Polgreen.
- Recruiting
- Registry status
- 1,250
- Enrollment target
- 1
- Study location
NCT05474417: Recruiting study of Kidney Diseases and Pancreatic Disease, sponsored by Philip Polgreen.
NCT05474417 is a study of Kidney Diseases and Pancreatic Disease that is actively recruiting participants, run by Philip Polgreen. The registered enrollment target is 1,250 participants, below the 1,753-participant average among 38 other Kidney Diseases trials with a reported enrollment target (29% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05474417, a study of Kidney Diseases and Pancreatic Disease, is actively recruiting participants, sponsored by Philip Polgreen.
- RECRUITING
- Registry status
- 1,250 participants
- Enrollment target
- 1
- Study location
Study Summary
The overarching hypothesis is that CF carriers are at increased risk for developing most of the extrapulmonary conditions associated with CF compared to the general population. Specifically, it is hypothesized that this pilot data will detect subclinical evidence of pancreatic and kidney disorders among CF carriers. This will be determined by bringing CF carriers and controls to the CRU for one visit where they will answer survey questions and undergo laboratory testing. Additionally, they will collect urine and stool samples at home that will be sent to outside laboratories for testing.
Primary Outcome
Comparison of glucose values in cystic fibrosis carrier group vs control group via t-tests.
Conditions Studied
Study Locations (1)
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,250 participants |
| Start Date | 2021-12-20 |
| Est. Completion | 2026-07 |
What NCT05474417 shows while recruiting
NCT05474417 is an observational study that tracks outcomes without assigning an intervention. Its 1,250 participants enrollment target places it among the larger protocols in the corpus, below the 1,753-participant average among 38 other Kidney Diseases trials with a reported enrollment target (29% lower).
The record links to 3 conditions, with Kidney Diseases appearing as the primary indexed condition, and to 0 interventions.
NCT05474417 reports a single indexed study location in Iowa.
Frequently Asked Questions
What is clinical trial NCT05474417 about?
NCT05474417 is a clinical study titled "The Effects of the CF Carrier State on the Kidneys and Pancreas". The overarching hypothesis is that CF carriers are at increased risk for developing most of the extrapulmonary conditions associated with CF compared to the general population. Specifically, it is hypothesized that this pilot data will detect subclinical evidence of pancreatic and kidney disorders a...
What is the current status of trial NCT05474417?
This trial is currently recruiting. The enrollment target is 1,250 participants. The study started on 2021-12-20. Estimated completion is 2026-07.
What conditions does trial NCT05474417 study?
This clinical trial studies the following conditions: Kidney Diseases, Pancreatic Disease, Carrier State.
Who is sponsoring clinical trial NCT05474417?
This trial is sponsored by Philip Polgreen, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05474417 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05474417's enrollment target sits among peer trials
1,250 5th of 38 higher than 34 of 38 other Kidney Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Collaborative Learning to Achieve Refined Interventions for Emory: Kidney Disease
RECRUITING · NA
-
Rutgers University Study of the Genetics of Kidney Disease
RECRUITING
-
Supporting VETerans With Kidney Disease Through Food As Medicine
RECRUITING · NA
-
Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients
RECRUITING · Phase 3
-
Methocarbamol vs Oxybutynin for Management of Pain and Discomfort S/P Ureteroscopy Procedure
RECRUITING · NA
-
Dietary Intervention to Improve Kidney Transplant Outcomes
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02743858 · 1,250 participants
Lymphedema Surveillance Study
- NCT04670874 · 1,250 participants
Quality of Life in Cutaneous Lymphoma Patients Using the Skindex29
- NCT04807868 · 1,250 participants
AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)
- NCT05995821 · 1,250 participants
Immunobiology Blood and Tissue Collection of Upper Aerodigestive Malignancies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI